Pathogenetic development patterns of respiratory and gastrointestinal pathologies in calves with proventriculus dysfunction history

An experiment was conducted in the conditions of an industrial complex specializing in the intensive fattening of young cattle, to study the development patterns of respiratory and gastrointestinal pathologies in calves with a history of previous proventriculus dysfunction. The object of the research were calves aged 120 days, which were divided into three groups: control, and two experimental groups - with a difference in using or the absence of phytosorbent. The diet included cereal hay and compound feed (CP 21.5%) according to the norms and regimen of feeding, for animals of this age. It appeared that for calves shortening of the adaptation period to the consumption of a large amount of compound feed had a negative impact on the rumen contractile function and the processes of digestion in it with the formation of a complex of symptoms of frothy tympany and rumen acidosis. After a course of appropriate treatment, the specific symptoms of these pathologies of the rumen disappeared, but the imbalance between the depression of symbiotic and activation of abdominal digestion remained, with the formation of a constant pre-threshold level of local autointoxication. The transfer of animals to the technological diet activated the processes of rumen metabolism and increased biochemical imbalance, which caused the progression of the endogenous intoxication syndrome and vegetative dystonia with a corresponding increase in the risk of developing respiratory and gastrointestinal pathologies. The use of a combined native premix based on the enterosorbent Rigatirin against the background of residual pathological phenomena after proventriculus dysfunctions reduced the level of toxic substances in the rumen, which excluded the generalization of autointoxication with an increase in the functional load on the digestive organs. As a result, the mechanism of pathogenetic integration (predisposition) formation in the body was leveled with a corresponding decrease in the incidence of the lungs, rumen and intestines. As a result, the mechanism of pathogenetic integration (predisposition) formation in the body was leveled, which caused a 6.7-fold decrease in the level of morbidity in animals and a 22.9 % increase in their growth

In Mice, Tuberculosis Progression Is Associated with Intensive Inflammatory Response and the Accumulation of Gr-1dim Cells in the Lungs

Infection with Mycobacterium tuberculosis (Mtb) results in different clinical outcomes ranging from asymptomatic containment to rapidly progressing tuberculosis (TB). The mechanisms controlling TB progression in immunologically-competent hosts remain unclear.To address these mechanisms, we analyzed TB progression in a panel of genetically heterogeneous (A/SnxI/St) F2 mice, originating from TB-highly-susceptible I/St and more resistant A/Sn mice. In F2 mice the rates of TB progression differed. In mice that did not reach terminal stage of infection, TB progression did not correlate with lung Mtb loads. Nor was TB progression correlated with lung expression of factors involved in antibacterial immunity, such as iNOS, IFN-gamma, or IL-12p40. The major characteristics of progressing TB was high lung expression of the inflammation-related factors IL-1beta, IL-6, IL-11 (p<0.0003); CCL3, CCL4, CXCL2 (p<0.002); MMP-8 (p<0.0001). The major predictors of TB progression were high expressions of IL-1beta and IL-11. TNF-alpha had both protective and harmful effects. Factors associated with TB progression were expressed mainly by macrophages (F4-80(+) cells) and granulocytes (Gr-1(hi)/Ly-6G(hi) cells). Macrophages and granulocytes from I/St and A/Sn parental strains exhibited intrinsic differences in the expression of inflammatory factors, suggesting that genetically determined peculiarities of phagocytes transcriptional response could account for the peculiarities of gene expression in the infected lungs. Another characteristic feature of progressing TB was the accumulation in the infected lungs of Gr-1(dim) cells that could contribute to TB progression.In a population of immunocompetent hosts, the outcome of TB depends on quantitatively- and genetically-controlled differences in the intensity of inflammatory responses, rather than being a direct consequence of mycobacterial colonization. Local accumulation of Gr-1(dim) cells is a newly identified feature of progressing TB. High expression of IL-1beta and IL-11 are potential risk factors for TB progression and possible targets for TB immunomodulation

An Interferon-Related Signature in the Transcriptional Core Response of Human Macrophages to Mycobacterium tuberculosis Infection

The W-Beijing family of Mycobacterium tuberculosis (Mtb) strains is known for its high-prevalence and -virulence, as well as for its genetic diversity, as recently reported by our laboratories and others. However, little is known about how the immune system responds to these strains. To explore this issue, here we used reverse engineering and genome-wide expression profiling of human macrophage-like THP-1 cells infected by different Mtb strains of the W-Beijing family, as well as by the reference laboratory strain H37Rv. Detailed data mining revealed that host cell transcriptome responses to H37Rv and to different strains of the W-Beijing family are similar and overwhelmingly induced during Mtb infections, collectively typifying a robust gene expression signature (“THP1r2Mtb-induced signature”). Analysis of the putative transcription factor binding sites in promoter regions of genes in this signature identified several key regulators, namely STATs, IRF-1, IRF-7, and Oct-1, commonly involved in interferon-related immune responses. The THP1r2Mtb-induced signature appeared to be highly relevant to the interferon-inducible signature recently reported in active pulmonary tuberculosis patients, as revealed by cross-signature and cross-module comparisons. Further analysis of the publicly available transcriptome data from human patients showed that the signature appears to be relevant to active pulmonary tuberculosis patients and their clinical therapy, and be tuberculosis specific. Thus, our results provide an additional layer of information at the transcriptome level on mechanisms involved in host macrophage response to Mtb, which may also implicate the robustness of the cellular defense system that can effectively fight against genetic heterogeneity in this pathogen

Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1\u3b2-induced autophagy article

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), has infected over 1.7 billion people worldwide and causes 1.4 million deaths annually. Recently, genome sequence analysis has allowed the reconstruction of Mycobacterium tuberculosis complex (MTBC) evolution, with the identification of seven phylogeographic lineages: four referred to as evolutionarily "ancient", and three "modern". The MTBC strains belonging to "modern" lineages appear to show enhanced virulence that may have warranted improved transmission in humans over ancient lineages through molecular mechanisms that remain to be fully characterized. To evaluate the impact of MTBC genetic diversity on the innate immune response, we analyzed intracellular bacterial replication, inflammatory cytokine levels, and autophagy response in human primary macrophages infected with MTBC clinical isolates belonging to the ancient lineages 1 and 5, and the modern lineage 4. We show that, when compared to ancient lineage 1 and 5, MTBC strains belonging to modern lineage 4 show a higher rate of replication, associated to a significant production of proinflammatory cytokines (IL-1\u3b2, IL-6, and TNF-\u3b1) and induction of a functional autophagy process. Interestingly, we found that the increased autophagic flux observed in macrophages infected with modern MTBC is due to an autocrine activity of the proinflammatory cytokine IL-1\u3b2, since autophagosome maturation is blocked by an interleukin-1 receptor antagonist. Unexpectedly, IL-1\u3b2-induced autophagy is not disadvantageous for the survival of modern Mtb strains, which reside within Rab5-positive phagosomal vesicles and avoid autophagosome engulfment. Altogether, these results suggest that autophagy triggered by inflammatory cytokines is compatible with a high rate of intracellular bacilli replication and may therefore contribute to the increased pathogenicity of the modern MTBC lineages

Сравнение эффективности и токсичности афлиберцепта и бевацизумаба в комбинации с режимом FOLFIRI во 2‑й линии лечения пациентов с метастатическим раком толстой кишки: ретроспективный анализ многоцентрового исследования

Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patients with metastatic colon cancer treated in 9 clinics in the Russian federation. The inclusion criteria were as follows: metastatic or locally advanced colon cancer; treatment with bevacizumab or aflibercept plus fOLfIRI in the second-line therapy. The primary outcome measure was progression-free survival (PfS). Secondary outcome measures included objective response rate and incidence of adverse events.Results. A total of 271 patients with metastatic colon cancer who received second-line therapy with bevacizumab (n = 81) or aflibercept (n = 190) between 2014 and 2018 were selected for this study. Study groups were matched for main prognostic signs. The objective response rate was 18.1 % in the bevacizumab group and 20.5 % in the aflibercept group (p = 0.7). The median PfS was 5 months (95 % confidence interval 3.8–6.1) in the aflibercept group and 7 months (95 % confidence interval 0.81–2.1) in the bevacizumab group (hazard ratio 1.4; 95 % confidence interval 0.99–2.1; p = 0.04). multivariate regression analysis demonstrated that the type of the targeted drug independently had no effect on PfS (hazard ratio 1.3; 95 % confidence interval 0.9–1.9; p = 0.2). we observed no statistically significant differences in the incidence of complications of any grades between the groups (58 % vs 72 %, p = 0.1). Patients receiving aflibercept were more likely to develop grade III–Iv arterial hypertension (2 % vs 9.5 %) and diarrhea (0 % vs 5.4 %), whereas thrombotic complications were more common in the bevacizumab group (10 % vs 1.8 %).Conclusion. we observed no significant differences in objective response rate and PfS between patients with metastatic colon cancer receiving bevacizumab or aflibercept in combination with fOLfIRI as second-line therapy. The toxicity profiles were different. Our findings can be used for choosing an optimal targeted drug for second-line treatment.Цель исследования – сравнение эффективности и токсичности афлиберцепта и бевацизумаба в комбинации с режимом fOLfIRI во 2-й линии лечения пациентов с метастатическим раком толстой кишки.Материалы и методы. Проведен ретроспективный анализ базы данных пациентов с метастатическим раком толстой кишки в рамках наблюдательного исследования работы 9 клиник РФ. Критерии включения в исследование: больные метастатическим или местно-распространенным раком толстой кишки; проведение терапии с включением бевацизумаба или афлиберцепта в комбинации с режимом fOLfIRI во 2-й линии лечения. Основной критерий эффективности – выживаемость без прогрессирования (ВбП). дополнительные критерии: частота объективных эффектов, частота развития нежелательных явлений.Результаты. Отобран 271 пациент с метастатическим раком толстой кишки, которым в 2014–2018 гг. проводилась 2-я линия терапия с включением бевацизумаба (n = 81) и афлиберцепта (n = 190). группы статически значимо не различались по основным прогностическим признакам. частота объективных эффектов составила 18,1 % в группе бевацизумаба и 20,5 % в группе афлиберцепта (р = 0,7). медиана ВбП составила 5 мес (95 % доверительный интервал 3,8–6,1) в группе афлиберцепта и 7 мес (95 % доверительный интервал 0,81–2,1) в группе бевацизумаба (отношение рисков 1,4; 95 % доверительный интервал 0,99–2,1; р = 0,04). многофакторный регрессионный анализ не подтвердил независимого влияния характера таргетного препарата на ВбП (отношение рисков 1,3; 95 % дИ 0,9–1,9; р = 0,2). Не отмечено статистически значимых различий в частоте развития осложнений всех степеней (58 % против 72 %, р = 0,1); среди негематологических осложнений артериальная гипертензия III–Iv степени (2 % против 9,5 %) и диарея (0 % против 5,4 %) чаще наблюдались в группе афлиберцепта, тромботические осложнения чаще наблюдались в группе бевацизумаба (10 % против 1,8 %).Выводы. Не отмечено статистически значимых различий между бевацизумабом и афлиберцептом в сочетании с режимом fOLfIRI во 2-й линии терапии пациентов с метастатическим раком толстой кишки ни в отношении достижения объективного эффекта, ни в отношении ВбП. Профили токсических реакций были различными. Полученные данные можно учитывать при выборе таргетного препарата во 2-й линии терапии

Токсичность и эффективность комбинации гемцитабина и nab-паклитаксела (паклитаксел + альбумин) в Российской популяции больных раком поджелудочной железы: результаты многоцентрового ретроспективного исследования

Introduction. The results of randomized MPACT study have demonstrated that the addition of nab-paclitaxel to gemcitabine leads to a statistically significant increase in life expectancy. The main objective of this retrospective study was to obtain up-to-date efficacy and toxicity data for this drug combination in Russian real-world clinical setting.Materials and methods. The study enrolled patients with morphologically confirmed locally advanced or metastatic pancreatic cancer who had ECOG Performance Status scores of 0-2 and received treatment with gemcitabine and nab-paclitaxel. Immediate and long-term outcomes, as well as treatment toxicity and dose modifications, were assessed.Results. The study included 142 patients who received treatment from 2009 to 2019 at 17 centers in 11 regions of Russia. Full dose gemcitabine and nab-paclitaxel were administered at baseline in 74 % of the cases. The median number of chemotherapy cycles was 4 (range, from 1 to 16). Nab-paclitaxel dose was reduced in 32 % of the cases, and that of gemcitabine in 23 % of them. Regression analysis revealed no prognostic factors associated with increased toxicity of gemcitabine and nab-paclitaxel administration. However, previous use of two or more chemotherapy lines had an impact on decisions made by physicians, making them reduce the baseline dose of gemcitabine and/or nab-paclitaxel (OR=6.1, 95% CI 1.5-24.2, р=0.010). An objective response was assessed in 134 subjects with positive response observed in 34 cases (25.4 %). The median time to progression was found to be 6.1 months, and the median life expectancy was 14.2 months.Conclusions. The combination of gemcitabine and nab-paclitaxel exhibits comparatively high efficacy. The acceptable toxicity profile allows its use in selected patients even with ECOG 2 and in the presence of serious comorbidities.Введение. Результаты рандомизированного исследования MPACT продемонстрировали, что добавление к гемцитабину nab-паклитаксела приводит к статистически значимому увеличению продолжительности жизни. Задачей данного ретроспективного исследования является получение актуальных данных об эффективности и токсичности данной комбинации в реальной клинической практике в России.Материалы и методы. В исследование включались пациенты с морфологически доказанным местнораспространенным или метастатическим раком поджелудочной железы, имеющие общее состояние по шкале ECOG 0-2, которым проводилась терапия гемцитабином и nab-паклитакселом. Оценивались непосредственные и отдаленные результаты лечения, а также токсичность лечения и модификации доз препаратов.Результаты. В исследование включено 142 пациента, получивших лечение в период с 2009 по 2019 гг. в 17 центрах из 11 регионов России. Гемцитабин и nab-паклитаксел назначались исходно в полных дозах в 74% случаев. Медиана числа проведенных курсов химиотерапии составила 4 (1-16 курсов). В процессе химиотерапии доза nab-паклитаксела редуцировалась в 32 % случаев, гемцитабина — в 23 % случаев. Регрессионный анализ не выявил прогностических факторов, ассоциированных с повышенной токсичностью гемцитабина и nab-паклитаксела. Однако назначение ранее двух или более линий химиотерапии влияло на решение врачей в пользу исходной редукции дозы гемцитабина и/ или nab-паклитаксела (ОШ=6,1, 95 % ДИ 1,5-24,2, р=0,010). Оценка объективного эффекта произведена у 134 пациентов. Объективный ответ зарегистрирован в 34 (25,4%) случаях. Медиана времени без прогрессирования составила 6,1 месяца, медиана продолжительности жизни составила 14,2 месяца.Выводы. Комбинация гемцитабина и nab-паклитаксела обладает сравнительно высокой эффективностью. Приемлемый профиль токсичности позволяет применять ее у отобранных пациентов даже при статусе ECOG 2 и наличии серьезной сопутствующей патологии

Association of Tuberculosis and Infections of Herpes Simplex, Varicella Zoster Viruses and Cytomegalovirus

To determine frequency of Herpes simplex (HSV), Varicella zoster viral (VZV) and Сytomegaloviral (CMV) coinfection with tuberculosis (TB) we examined 45 patients with pulmonary TB and 62 healthy donors, 25 of them were healthcare workers in tuberculosis hospital and the rest 37 had no previous contact with TB. None of the participants had vesicular rash of skin or mucosa. For diagnosis of herpes viral infection enzyme-linked immunosorbent assay for detection of HSV, VZV, CMV IgG in PBMC supernatants was performed. A significant increase in CMV (53.3%) and HSV (40%) infection in TB patients was observed comparing to healthy donors (p &lt; 0.05; 19.4 and 16.1% respectively). Frequency of VZV infection in TB patients (17.8%) and healthy donors (8.1%) differed statistically unsignificantly. Levels of specific IgG secretion in PBMC culture in both groups in case of VZV and CMV infections didn’t differ, but in case of HSV coinfection in TB patients mean level of HSV IgG secretion (1.106 ± 0.297 OD) significantly exceeded mean level of HSV IgG in PBMC supernatants of healthy donors with asymptomatic HSV infection (0.285 ± 0.048 OD, р &lt; 0,05). The obtained data give evidence of an association of pulmonary TB and herpes viral infections. Influence of these coinfections on course and morbidity of TB requires further research

Metallic Mercury in the Soft Tissues of the Hand: Case Report

Background. The likelihood of foreign bodies presence in the wound exists in almost any injury to the skin. The consequences of their ingress into the body are extremely varied: from the complete absence of symptoms to systemic toxicity, depending both on the nature of the embedded agent and on the way of its penetration. The data of the anamnesis and clinical examination of foreign bodies are not always convincing, and the results of conventional radiography, even with X-ray-positive foreign bodies, are often nonspecific. The parenteral ingression of metallic mercury is rare. In contrast to its access through the respiratory or digestive tract, this route has not been adequately studied. This clinical report is devoted to the clinical case of deliberate self-administration of metallic mercury into the soft tissues of the upper limb. Clinical case description. A 24-year-old patient sought medical help 2 years after the injury and tried to hide its circumstances during taking his anamnesis. Ultrasound played a decisive role in making the diagnosis (foreign body) and revealing its nature (metallic mercury). This indicates the high information content and specificity of ultrasound which exceeded the X-ray capabilities. Despite no signs of general and local toxicity, the presence of mercury in the body is unacceptable and requires the surgical treatment. Our case showed that mercury in soft tissues was limited to granuloma or was fixed inside fibrous tissue. This made it possible to remove it radically. Conclusion. Our observation suggests that ultrasound, in contrast to X-ray, is able to present a specific picture of the existence of metallic mercury in soft tissues. Therefore, it is advisable to include ultrasound in the examination algorithm if any foreign body (especially mercury) is suspected to detect or clarify its nature. If mercury is detected in soft tissues, the radical surgical treatment can be successfully performed, since the reaction of tissues around the mercury material (in the form of granuloma and the confinement of mercury spheres in a conglomerate of fibrous tissue) makes it possible to avoid the spread of mercury along the wound channel

Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs

Local immune reactivity in the lungs of BALB/c mice was studied following (i) intranasal (i.n.) vaccination with Mycobacterium bovis BCG, (ii) intravenous (i.v.) challenge with a virulent M. bovis field isolate and (iii) i.n. vaccination with M. bovis BCG followed by i.v. challenge with an M. bovis field isolate. The results demonstrated that i.n. vaccination with BCG induced a high degree of protection against systemic M. bovis challenge, and that this protection correlated with a rapid production of IFN-γ after M. bovis challenge by lung T cells from vaccinated mice